Results From Phase 2 CodeBreaK 100 Show LUMAKRAS™ (sotorasib) Is The First And Only KRAS G12C Inhibitor With Overall Survival Data Read more about Results From Phase 2 CodeBreaK 100 Show LUMAKRAS™ (sotorasib) Is The First And Only KRAS G12C Inhibitor With Overall Survival Data
Phase 2 Fight Trial Continues To Show Improved Overall Survival With Bemarituzumab Plus Chemotherapy In Patients With FGFR2b+ Gastric And Gastroesophageal Cancers Read more about Phase 2 Fight Trial Continues To Show Improved Overall Survival With Bemarituzumab Plus Chemotherapy In Patients With FGFR2b+ Gastric And Gastroesophageal Cancers
Amgen to Webcast Investor Meeting at ASCO 2021 Read more about Amgen to Webcast Investor Meeting at ASCO 2021
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis Read more about Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Amgen To Present At The 2021 Jefferies Healthcare Conference Read more about Amgen To Present At The 2021 Jefferies Healthcare Conference
FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Read more about FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Amgen To Present AT the Cowen 2nd Annual Virtual Oncology Innovation Summit Read more about Amgen To Present AT the Cowen 2nd Annual Virtual Oncology Innovation Summit
Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021 Read more about Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021
New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients Read more about New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients
